| Followers | 16 |
| Posts | 1805 |
| Boards Moderated | 0 |
| Alias Born | 07/21/2013 |
Sunday, June 20, 2021 5:33:54 AM
I agree 100%, and it is Buffet/Munger's advice that has me overweight in AVXL.
But there's a saying which I hold near and dear.
"Don't fool yourself and you're the easiest person to fool."
Most on this board would agree (some begrudgingly) that AVXL is a risky investment.
Those agreeing begrudgingly would do so with a wink and a nod as if to say " But not really!"
I cry "foul!".
It's a startup Biotech running trials on the most frail and vulnerable people society has.
And involving the blood/brain Barrier no less.
A few unexplained deaths and a trial halt(which we saw in a recent BP vaccine trial) and the narrative changes, especially if BP has influence and the ears of people within the FDA/TGA.
One of the recent arguments I've heard is posters say is if they were to sell some shares they have nowhere else compelling to invest the money.
If they have a position in a dozen biotech stocks( which I have read is the only sensible way to invest in the biotech space. I believe Investor2014 employs this strategy) then they make a valid argument.
But if AVXL is their only biotech(as is my case) and it's a large % of their investment mix I might suggest they sell some shares and keep the money in cash as I do.
In my mind high risk +low risk balances out to acceptable risk.
I'm in total agreement with the longs that AVXL has the potential to make us all silly rich, but "too good to be true" has also stood the test of time.
(exiting soapbox now.)
But there's a saying which I hold near and dear.
"Don't fool yourself and you're the easiest person to fool."
Most on this board would agree (some begrudgingly) that AVXL is a risky investment.
Those agreeing begrudgingly would do so with a wink and a nod as if to say " But not really!"
I cry "foul!".
It's a startup Biotech running trials on the most frail and vulnerable people society has.
And involving the blood/brain Barrier no less.
A few unexplained deaths and a trial halt(which we saw in a recent BP vaccine trial) and the narrative changes, especially if BP has influence and the ears of people within the FDA/TGA.
One of the recent arguments I've heard is posters say is if they were to sell some shares they have nowhere else compelling to invest the money.
If they have a position in a dozen biotech stocks( which I have read is the only sensible way to invest in the biotech space. I believe Investor2014 employs this strategy) then they make a valid argument.
But if AVXL is their only biotech(as is my case) and it's a large % of their investment mix I might suggest they sell some shares and keep the money in cash as I do.
In my mind high risk +low risk balances out to acceptable risk.
I'm in total agreement with the longs that AVXL has the potential to make us all silly rich, but "too good to be true" has also stood the test of time.
(exiting soapbox now.)
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
